News Briefing channel feed

Take­da high­lights promis­ing front­line re­sults for ALK+ NSCLC drug Alun­brig; TGTX shares plunge on PhI­II sna­fu

7 years ago

Chi­nese biotech in­vestors are pour­ing bil­lions in­to US com­pa­nies; Nek­tar part­ners with BioX­cel on new I/O triple

7 years ago

Bay­er wins OK for he­mo­phil­ia A treat­ment; Agenus sells off a slice of fu­ture roy­al­ties for $15M

7 years ago

Bri­an Gal­lagher jumps from SR One to run­ning the Boston of­fice for Abing­worth; Por­to­la goes with com­mer­cial vet for new CEO

7 years ago

UK ad­vis­es against cov­er­ing No­var­tis' Kym­ri­ah for adults; Ex-Mast chief Bri­an Cul­ley ap­point­ed CEO at Bi­o­Time

7 years ago

As­traZeneca touts ex­tend­ed safe­ty and ef­fi­ca­cy da­ta on Fasen­ra; Vanes­sa King takes the helm at Viri­on

7 years ago

Ar­genx buoyed by PhII tri­al re­sults; Boehringer touts a big batch of re­al-world COPD da­ta

7 years ago

Hua Med­i­cine reaps $110.5M, ad­just­ing ex­pec­ta­tions for Hong Kong IPO

7 years ago

Gala­pa­gos rais­es $300M on the back of first PhI­II fil­go­tinib suc­cess; In­cyte push­es in­to PhI­II with top­i­cal Jakafi

7 years ago

Foamix stock bub­bles high­er on lat­est ac­ne PhI­II; Con­cen­tric Anal­gesic gets an FDA 'break­through'

7 years ago

Pfiz­er, Mer­ck KGaA tout PhI­II suc­cess for Baven­cio; Im­mun­sanT gets a new in­vest­ment from JDRF

7 years ago

NHS re­fus­es to cov­er Ocre­vus for pri­ma­ry pro­gres­sive MS; OxStem taps vet­er­an drug hunter Georg Ter­stap­pen as CSO

7 years ago

Ar­row­head touts hep B da­ta, shares rock­et up; Eli Lil­ly's an­i­mal health unit files big IPO

7 years ago

What's up at Im­muno­core?; Pfiz­er nabs a key 'break­through'; Adap­ti­m­mune rais­es $100M

7 years ago

Brain­storm re­cruits No­var­tis vet Araya as chief com­mer­cial of­fi­cer; Roche out-li­cens­es IPF drug to Shang­hai's Ark

7 years ago

Chi­na reg­u­la­tors launch a re­view for BeiGene’s PD-1; PureTech co-founder hops to Long­wood Fund

7 years ago

Al­ny­lam makes RNAi his­to­ry again as patisir­an gets ap­proved in Eu­rope; Ver­tex buys in­to UK-based ma­chine learn­ing group

7 years ago

Emer­gent snags opi­oid drug in $735M buy­out deal; Ger­many frets about post-Brex­it dis­rup­tion in drug mar­ket

7 years ago

Are­na's di­et drug castoff deemed safe in study; UK price over­seers say break­through CAR-T Yescar­ta is too ex­pen­sive

7 years ago

Mag­no­lia bags a $20M CPRIT grant to back tri­al work on new drug; Evotec lines up a new part­ner on rare ge­net­ic dis­eases

7 years ago

Chi­na Bi­o­log­ic re­jects $3.9B buy­out bid from ex-CEO; Leo Phar­ma bags atopic der­mati­tis drug for $17M up­front

7 years ago

New co-CEO named at WuXi; Bris­tol-My­ers gets pri­or­i­ty re­view for myelo­ma com­bo fea­tur­ing Em­plic­i­ti

7 years ago

Pfiz­er inks mar­ket­ing deal for col­orec­tal can­cer test; Zai Lab dous­es a hot ru­mor about a Hong Kong IPO

7 years ago

Rex­ahn inks Keytru­da com­bo col­lab­o­ra­tion in breast can­cer; Achillion hires uniQure's Steven Ze­lenkofske as new CMO

7 years ago
First page Previous page 56575859606162 Next page Last page
A service from the Financial Times